X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4091) 4091
Newspaper Article (109) 109
Newsletter (57) 57
Magazine Article (18) 18
Dissertation (11) 11
Book Chapter (7) 7
Conference Proceeding (5) 5
Publication (5) 5
Streaming Video (3) 3
Book Review (1) 1
Reference (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2695) 2695
insulin glargine (2580) 2580
insulin (1942) 1942
endocrinology & metabolism (1853) 1853
diabetes mellitus, type 2 - drug therapy (1630) 1630
female (1539) 1539
male (1477) 1477
diabetes (1444) 1444
type 2 diabetes (1385) 1385
hypoglycemic agents - therapeutic use (1352) 1352
glargine (1329) 1329
middle aged (1170) 1170
hypoglycemic agents - administration & dosage (1087) 1087
insulin - analogs & derivatives (1084) 1084
hypoglycemia (1020) 1020
glycemic control (932) 932
insulin - therapeutic use (925) 925
insulin, long-acting (858) 858
adult (812) 812
aged (808) 808
therapy (773) 773
insulin - administration & dosage (738) 738
nph insulin (718) 718
basal insulin (701) 701
diabetes mellitus, type 2 - blood (700) 700
glucose (691) 691
diabetes mellitus, type 1 - drug therapy (683) 683
hypoglycemic agents - adverse effects (650) 650
blood glucose - metabolism (642) 642
treatment outcome (632) 632
diabetes mellitus (620) 620
diabetes therapy (567) 567
blood glucose - drug effects (524) 524
care and treatment (518) 518
glycated hemoglobin a - metabolism (504) 504
medicine, general & internal (485) 485
hyperglycemia (480) 480
research (471) 471
internal medicine (462) 462
mellitus (455) 455
drug administration schedule (454) 454
type 1 diabetes (449) 449
hypoglycemia - chemically induced (440) 440
metformin (437) 437
drug therapy (422) 422
open-label (395) 395
insulin, long-acting - therapeutic use (391) 391
management (391) 391
efficacy (385) 385
pharmacology & pharmacy (381) 381
glycated hemoglobin a - analysis (379) 379
insulin - adverse effects (375) 375
drug therapy, combination (367) 367
analysis (365) 365
insulin, long-acting - administration & dosage (359) 359
medicine & public health (344) 344
insulin detemir (333) 333
clinical trials (329) 329
risk (329) 329
safety (327) 327
risk factors (326) 326
dosage and administration (321) 321
blood glucose - analysis (308) 308
to-target trial (290) 290
adolescent (284) 284
diabetes mellitus, type 1 - blood (280) 280
detemir (279) 279
glycosylated hemoglobin (277) 277
insulin glargine - therapeutic use (276) 276
blood sugar (263) 263
health aspects (259) 259
type 2 diabetes mellitus (258) 258
dose-response relationship, drug (250) 250
trial (244) 244
glucose control (242) 242
patients (241) 241
diabetes mellitus - drug therapy (239) 239
people (237) 237
insulin glargine - administration & dosage (234) 234
endocrinology (231) 231
body mass index (228) 228
retrospective studies (226) 226
pharmacokinetics (225) 225
dextrose (223) 223
exenatide (221) 221
animals (219) 219
hypoglycemia - prevention & control (216) 216
lispro (214) 214
double-blind (212) 212
hypoglycemic agents (211) 211
insulin, long-acting - adverse effects (204) 204
diabetes mellitus, type 2 - complications (203) 203
mortality (203) 203
injections, subcutaneous (202) 202
type-2 (201) 201
hypoglycemic agents - pharmacology (200) 200
insulin, isophane - therapeutic use (200) 200
time factors (200) 200
liraglutide (196) 196
randomized controlled trials as topic (196) 196
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3956) 3956
German (181) 181
Spanish (42) 42
French (41) 41
Japanese (24) 24
Czech (19) 19
Hungarian (18) 18
Russian (18) 18
Portuguese (15) 15
Chinese (14) 14
Italian (6) 6
Korean (6) 6
Polish (5) 5
Swedish (5) 5
Turkish (5) 5
Norwegian (3) 3
Dutch (2) 2
Finnish (2) 2
Slovenian (2) 2
Bosnian (1) 1
Breton (1) 1
Danish (1) 1
Georgian (1) 1
Lithuanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 8, pp. 723 - 732
Journal Article
Diabetic medicine, ISSN 0742-3071, 04/2016, Volume 33, Issue 4, pp. 471 - 477
Aims To assess resource utilization associated with severe hypoglycaemia across three insulin regimens in a large phase 3a clinical programme involving people... 
GLYCEMIC CONTROL | 26-WEEK | GLARGINE | NAIVE PATIENTS | ENDOCRINOLOGY & METABOLISM | OPEN-LABEL | TO-TARGET TRIAL | BEGIN | BASAL-BOLUS TREATMENT | TYPE-2 | DEGLUDEC/INSULIN ASPART | Hypoglycemia - therapy | Hypoglycemic Agents - economics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Insulin Detemir - therapeutic use | Insulin Detemir - economics | Clinical Trials, Phase III as Topic | Hypoglycemic Agents - administration & dosage | Hypoglycemic Agents - therapeutic use | Sitagliptin Phosphate - administration & dosage | Costs and Cost Analysis | Administration, Oral | Drug Therapy, Combination - economics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Insulin Aspart - economics | Insulin, Long-Acting - adverse effects | Insulin, Long-Acting - administration & dosage | Diabetes Mellitus, Type 1 - economics | Diabetes Mellitus, Type 1 - blood | Insulin, Long-Acting - therapeutic use | Hypoglycemic Agents - adverse effects | Insulin Aspart - adverse effects | Cohort Studies | Insulin Aspart - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Diabetes Mellitus, Type 2 - economics | Insulin, Long-Acting - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Insulin Aspart - administration & dosage | Insulin Detemir - administration & dosage | Insulin Detemir - adverse effects | Hypoglycemia - physiopathology | Adult | Hypoglycemia - economics | Hypoglycemia - chemically induced | Severity of Illness Index | Insulin Glargine - adverse effects | Drug Administration Schedule | Insulin Glargine - economics | Insulin Glargine - therapeutic use | Sitagliptin Phosphate - economics | Diabetes Mellitus, Type 1 - drug therapy | Diabetes Mellitus, Type 2 - blood | Health Care Costs | Sitagliptin Phosphate - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Combinations | Sitagliptin Phosphate - adverse effects | Type 2 diabetes | Adults | Type 1 diabetes | Insulin | Analysis | Emergency medical care | Diabetes | Hypoglycemia | Complications | Research
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 12/2015, Volume 17, Issue 12, pp. 1142 - 1149
Journal Article
Journal Article
Internal medicine (Tokyo, 1992), ISSN 1349-7235, 2018, Volume 57, Issue 10, pp. 1381 - 1389
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 02/2016, Volume 18, Issue 2, pp. 159 - 168
Aims To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin... 
insulin antibody | biosimilar insulin | insulin glargine | LY2963016 insulin glargine | Insulin glargine | Insulin antibody | Biosimilar insulin | CONTROLLED-TRIAL | RESPONSES | EFFICACY | SAFETY | ENDOCRINOLOGY & METABOLISM | NAIVE | Immunogenetic Phenomena - drug effects | Recombinant Proteins - therapeutic use | Insulin, Regular, Human - genetics | Humans | Diabetes Mellitus, Type 1 - complications | Insulin Antibodies - analysis | Recombinant Proteins - adverse effects | Incidence | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - immunology | Diabetes Mellitus, Type 1 - immunology | Drug Hypersensitivity - complications | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Drug Hypersensitivity - etiology | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Biosimilar Pharmaceuticals - therapeutic use | Insulin Glargine - adverse effects | Double-Blind Method | Insulin Glargine - therapeutic use | Asymptomatic Diseases - epidemiology | Insulin, Regular, Human - adverse effects | Insulin, Regular, Human - analogs & derivatives | Insulin, Regular, Human - therapeutic use | Biosimilar Pharmaceuticals - adverse effects | Diabetes Mellitus, Type 1 - drug therapy | Cross Reactions | Insulin Glargine - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Drug Hypersensitivity - epidemiology | Drug Hypersensitivity - immunology | Diabetes Mellitus, Type 1 - blood | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Comparative analysis | Insulin | Original
Journal Article
Journal Article
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2016, Volume 18, Issue 4, pp. 366 - 374
Aims To compare the efficacy and safety of insulin glargine 300 U/ml (Gla‐300) with glargine 100 U/ml (Gla‐100) in Japanese people with type 2 diabetes using... 
basal insulin | glycaemic control | type 2 diabetes | insulin analogues | randomized trial | phase III study | Phase III study | Type 2 diabetes | Insulin analogues | Randomized trial | Basal insulin | Glycaemic control | GLYCEMIC CONTROL | ENDOCRINOLOGY & METABOLISM | MELLITUS | PROVIDES | UNITS/ML | Glycated Hemoglobin A - analysis | Japan - epidemiology | Hypoglycemia - epidemiology | Follow-Up Studies | Drug Resistance, Multiple | Humans | Middle Aged | Insulin Detemir - therapeutic use | Male | Risk | Delayed-Action Preparations - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemia - prevention & control | Insulin Glargine - administration & dosage | Drug Therapy, Combination - adverse effects | Hypoglycemic Agents - administration & dosage | Insulin Detemir - adverse effects | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Insulin Glargine - adverse effects | Administration, Oral | Insulin Glargine - therapeutic use | Diabetes Mellitus, Type 2 - blood | Delayed-Action Preparations - adverse effects | Delayed-Action Preparations - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Hemoglobin | Glucose | Insulin | Dextrose | Diabetes therapy | Confidence intervals | Diabetes | Hypoglycemia | Body mass index | Diabetes mellitus | Diabetes mellitus (non-insulin dependent) | Evidence-based medicine | Original
Journal Article
Journal Article